User profiles for Christopher Hulme

Christopher Hulme

Professor Drug Discovery/Medicinal Chemistry, University of Arizona
Verified email at pharmacy.arizona.edu
Cited by 9053

" Multi-component reactions: emerging chemistry in drug discovery"'from xylocain to crixivan'

C Hulme, V Gore - Current medicinal chemistry, 2003 - ingentaconnect.com
With the recent emergence of combinatorial chemistry and high-speed parallel synthesis for
drug discovery applications, the multi-component reaction (MCR) has seen a resurgence of …

New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the …

…, PR Menard, DL Cheney, C Hulme… - Journal of medicinal …, 1999 - ACS Publications
A new 4-point pharmacophore method for molecular similarity and diversity that rapidly
calculates all potential pharmacophores/pharmacophoric shapes for a molecule or a protein site …

Maximizing synthetic efficiency: Multi‐component transformations lead the way

H Bienaymé, C Hulme, G Oddon… - Chemistry–A European …, 2000 - Wiley Online Library
With the emergence of high‐throughput screening in the pharmaceutical industry in the
early 1990's, organic chemists were faced with a new challenge: how to prepare large …

Health outcome measures in the evaluation of total hip arthroplasties—a comparison between the Harris hip score and the Oxford hip score

Y Kalairajah, K Azurza, C Hulme, S Molloy… - The Journal of …, 2005 - Elsevier
There has been an increasing need for the sensitive and reproducible measurement of the
outcome after hip surgery. Numerous hip scoring systems, varying in their complexity and …

Hypervalent iodine chemistry: new oxidation reactions using the iodosylbenzene− trimethylsilyl azide reagent combination. Direct α-and β-azido functionalization of …

…, J Lacour, PA Evans, MB Roe, C Hulme - Journal of the …, 1996 - ACS Publications
Treatment of triisopropylsilyl (TIPS) enol ethers with PhIO/TMSN 3 /at −18 to −15 C rapidly (5
min) gave β-azido TIPS enol ethers in high yields, with only traces of the α-azido adduct. …

The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and …

J Dietrich, C Hulme, LH Hurley - Bioorganic & medicinal chemistry, 2010 - Elsevier
The majority of kinase inhibitors developed to date are competitive inhibitors that target the
ATP binding site; however, recent crystal structures of Gleevec® (imatinib mesylate, STI571, …

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

…, V Gokhale, T Dunckley, C Hulme - ACS chemical …, 2012 - ACS Publications
With 24.3 million people affected in 2005 and an estimated rise to 42.3 million in 2020, dementia
is currently a leading unmet medical need and costly burden on public health. Seventy …

Emerging molecular diversity from the intra-molecular Ugi reaction: iterative efficiency in medicinal chemistry

C Hulme, J Dietrich - Molecular diversity, 2009 - Springer
This review details a now established area within the isonitrile multi-component reaction (IMCR)
field of study, namely employing bi-functional reagents in the Ugi reaction for the …

Dyrk1 inhibition improves Alzheimer's disease‐like pathology

…, V Gokhale, AY Shaw, C Foley, B Smith, C Hulme… - Aging cell, 2017 - Wiley Online Library
There is an urgent need for the development of new therapeutic strategies for Alzheimer's
disease ( AD ). The dual‐specificity tyrosine phosphorylation‐regulated kinase‐1A (Dyrk1a) is …

Novel applications of ethyl glyoxalate with the Ugi MCR

C Hulme, MP Cherrier - Tetrahedron letters, 1999 - Elsevier
This letter describes novel high-yielding solution phase preparations of 1,4-benzodiazepine-2,5-dione,
diketo-piperazine, ketopiperazine and dihydroquinoxalinone libraries via a UDC (…